PsychonautWiki Archive

1P-ETH-LAD

Revision as of 23:00, 5 November 2016 by >Dextromethorphan (→Chemistry)

1-propionyl-6-ethyl-6-nor-lysergic acid diethyamide (abbreviated 1P-ETH-LAD) is a semi-synthetic psychedelic hallucinogenic drug of the lysergamide family. It has recently been marketed since early 2016 and is almost completely unknown.

1P-ETH-LAD
Chemical Nomenclature
Common names 1P-ETH-LAD
Substitutive name 1-propionyl-6-ethyl-6-nor-lysergic acid diethyamide
Systematic name (6aR,9R)-4-propionyl-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
Class Membership
Psychoactive class Psychedelic
Chemical class Lysergamide
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



⇣ Oral
Dosage
Threshold 25 µg
Light 30 - 60 µg
Common 60 - 100 µg
Strong 100 - 200 µg
Heavy 200 µg +
Duration
Total 6 - 12 hours
Onset 30 - 90 minutes
Peak 2 - 4 hours
Offset 2 - 4 hours
After effects 6 - 24 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Summary sheet: 1P-ETH-LAD

This substance has little to no history of human usage. However, it has recently become commonly marketed as a legal alternative to LSD through online research chemical vendors.

Chemistry

1P-ETH-LAD, or 1-propionyl-6-ethyl-6-nor-lysergic acid diethyamide, is a semi-synthethic alkaloid of the lysergamide famiy. 1P-ETH-LAD is a structural analogue of lysergic acid, with an N,N-diethylamide functional group bound to RN of the chemical structure. This core polycyclic structure is an indole derivative, and has tryptamine and phenethylamine groups embedded within it.

1P-ETH-LAD's structure contains a bicyclic hexahydroindole fused to a bicyclic quinoline group (nor-lysergic acid). 1P-ETH-LAD does not contain a methyl group substituted at R6 of its nor-lysgeric acid skeleton, this is represented by the nor- prefix. Instead, 1P-ETH-LAD is substituted at R6 with an ethyl group and at R1 with a propionyl group. At carbon 8 of the quinoline a N,N-diethyl carboxamide is bound.

1P-ETH-LAD is a chiral compound with two stereocenters at R5 and R8. 1P-ETH-LAD, also called (+)-D-1P-ETH-LAD, has an absolute configuration of (5R, 8R). The three other stereoisomers of 1P-ETH-LAD do not have psychoactive properties.[citation needed]

Pharmacology

Main article: Serotonergic psychedelic

This compound likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from 1P-ETH-LAD's efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

1P-ETH-LAD shares many common traits with its parent compound LSD; it appears to be roughly equal in potency as well as similar in mechanism although the progression and duration of effects are compressed (while remaining qualitatively less intense and more manageable) due to suspected differences in how it is metabolized. It is speculated that 1P-ETH-LAD is metabolized to ETH-LAD, just like 1P-LSD is likely metabolized to LSD.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

While the subjective effects are almost identical to that of LSD, 1P-ETH-LAD is significantly shorter in its duration and less uncomfortable in both its negative physical side effects and generalized anxiety.

Physical effects

  • Spontaneous tactile sensations - The "body high" of 1P-ETH-LAD can be described as proportionally intense in comparison to its accompanying visual and cognitive effects. It behaves as a euphoric, fast-moving, sharp and location specific tingling sensation. For some it is manifested spontaneously at different unpredictable points throughout the trip, but for most it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached. In comparison to LSD it is a little less sharp in its tingles, less likely to be uncomfortable but otherwise essentially identical.
  • Stimulation - In terms of its effects on the physical energy levels of the tripper, AL-LAD is usually considered to be very energetic and stimulating without being forced. For example, when taken in any environment it will usually encourage physical activities such as running, walking, climbing or dancing. In comparison, other more commonly used psychedelics such as psilocin are generally sedating and relaxing.
  • Bodily control enhancement
  • Increased heart rate
  • Nausea - Mild nausea is occasionally reported when consumed in moderate to high dosages and either passes instantly once the tripper has vomited or gradually fades by itself as the peak sets in.
  • Pupil dilation
  • Tactile enhancement - Feelings of enhanced tactile sensation are consistently present at moderate levels throughout most 1P-ETH-LAD trips.
  • Teeth grinding
  • Temperature regulation suppression

Cognitive effects

In comparison to other psychedelics such as psilocin, LSA and ayahuasca, 1P-ETH-LAD is significantly more stimulating and fast-paced in terms of the specific style of thought stream which it produces and contains a large number of potential effects associated with both psychedelic tryptamines and phenethylamines. In comparison to LSD it is often reported to be less anxiety-provoking and generally more emotionally comfortable and forgiving.

The most prominent of these cognitive effects generally include:

Visual effects

Enhancements

Distortions

Geometry

The visual geometry that is present throughout this trip can be described as more similar in appearance to that of LSD, 2C-B or 2C-I than Psilocin, LSA or DMT. It can be comprehensively described through its variations as primarily intricate in complexity, algorithmic in form, unstructured in organization, brightly lit, colourful in scheme, organic in feel, multicoloured in scheme, flat in shading, soft in its edges, large in size, slow in speed, smooth in motion, either angular or round in its corners, non-immersive in depth and consistent in intensity. At higher dosages, it consistently results in states of Level 8B visual geometry over Level 8A.

In comparison to LSD specifically, its geometry tends to be more rounded in its corners, slightly softer in its edges and slightly less intricate in its form. Aside from this it is otherwise identical in its appearance.

Hallucinatory states

1P-ETH-LAD is capable of producing a full range of low and high level hallucinatory states in a fashion that is a little less consistent and reproducible than that of many other commonly used psychedelics such as psilocin or DMT but considerably more likely when to compared to that of LSD. This can feel similar to the hallucinations which occur with 4-AcO-DMT but tends to occur almost exclusively at heavier dosages. These effects include:

Auditory effects

Toxicity and harm potential

 Main articles: Research chemicals § Toxicity and harm potential & Responsible use § Hallucinogens

The toxicity and long-term health effects of recreational 1P-ETH-LAD use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 1P-ETH-LAD is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried 1P-ETH-LAD suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

1P-ETH-LAD is not habit-forming and the desire to use it can actually decrease with use. Like with most psychedelics, it is thought to be most often self-regulating rather than self-reinforcing.

Tolerance to the effects of 1P-ETH-LAD are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). It should be noted that this only applies to the physiological tolerance -- mental or psychological tolerance is thought by some to take two weeks or more for the full experience to re-manifest.

Due to its activity at the 5-HT2A receptor, 1P-ETH-LAD presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of 1P-ETH-LAD all psychedelics (particularly tryptamines and other lysergamides) will display a reduced effect.

It is unclear in many countries whether this compound is legal or not and one should take precaution by assuming it is illegal to avoid legal issues.

  • USA - 1P-ETH-LAD is illegal in the U.S. under the analogue act.
  • UK - The U.K. ban, recommended by the ACMD on June 10th, 2014, came into effect on January 7th, 2015. AL-LAD was specifically named in the U.K. Misuse of Drugs Act as a Class A drug, despite admission from the ACMD that they were unable to identify any harm associated with its use.[1]
  • Switzerland - 21 additional chemicals were added to the list of illegal substances including AL-LAD in December 2015.[2]
  • Latvia - AL-LAD is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1th, 2015.[3]
  • Sweden - Following its sale as a designer drug, AL-LAD was made illegal in Sweden on 26 January 2016.[4]

Experience reports

Anecdotal reports which describe this compound within our experience index include:

Additional experience reports can be found here:

See also

References

  1. ↑ ACMD (10 June 2014). "Update of the Generic Definition for Tryptamines" (PDF). UK Home Office. p. 12. Retrieved 10 June 2014. 
  2. ↑ https://www.admin.ch/opc/de/official-compilation/2015/5093.pdf
  3. ↑ Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2.4.punkts) | http://likumi.lv/doc.php?id=121086
  4. ↑ (in Swedish) Folkhälsomyndigheten. | https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2016/januari/31-nya-substanser-klassas-som-narkotika-eller-halsofarlig-vara/
Retrieved from "https://psy.st/index.php?title=1P-ETH-LAD&oldid=397428"